皓元医药：关于使用部分募集资金向子公司增资以实施募投项目的公告

Core Viewpoint - Haoyuan Pharmaceutical announced the approval of a capital increase of 50 million yuan to its subsidiary, Ouchuang Biotechnology, for the implementation of the fundraising project "New Drug Technology R&D Center" [2] Group 1 - The fourth meeting of the Audit Committee of the fourth Board of Directors was held on November 19, 2025 [2] - The company plans to use part of the raised funds for the development of new drug technology [2] - The decision was made to support the subsidiary's project aimed at enhancing research and development capabilities [2]